Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database. admin8. November 2025
Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates from claims data. admin8. November 2025
Real-World Cost Difference in Patients With Psoriasis Initiating Apremilast vs. Secukinumab After Conventional Systemic Therapy Using German Sickness Fund Data. admin8. November 2025
Real-World Cost Difference in Patients with Psoriasis Newly Initiating Apremilast vs. Biologic Treatment after Conventional Systemic Therapy: A Retrospective Analysis of German Sickness Fund Data. admin8. November 2025
PSY17 REAL-WORLD COST DIFFERENCE IN PATIENTS WITH PSORIASIS NEWLY INITIATING APREMILAST VS. BIOLOGIC TREATMENT AFTER CONVENTIONAL SYSTEMIC THERAPY: A RETROSPECTIVE ANALYSIS OF GERMAN SICKNESS FUND DATA. admin8. November 2025
Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis. admin8. November 2025
Disease Burden, Healthcare Resource Utilization & Treatment Pattern among Patients with Prurigo Nodularis compared to a Benchmark in Germany: A Real-World-Evidence Claims Data Study. admin8. November 2025
Epidemiology of prurigo nodularis among SHI insured patients in germany: a claims database analysis ISPOR Europe 2019, Copenhagen, Denmark admin8. November 2025
CO65 Clinical and Economic Burden Among Patients With Prurigo Nodularis Compared to a Benchmark in Germany: A Real-World-Evidence Claims Data Study. Value in Health, 25(12), S. S30. admin8. November 2025
Comorbidities, healthcare resource utilization & treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: A real-world evidence claims data study. admin8. November 2025
